- Home
- PLL vs RVPHW Comparison
PLL vs RVPHW Comparison
Compare PLL & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLL
- RVPHW
- Stock Information
- Founded
- PLL 2016
- RVPHW 2018
- Country
- PLL United States
- RVPHW United States
- Employees
- PLL N/A
- RVPHW 15
- Industry
- PLL Other Metals and Minerals
- RVPHW Biotechnology: Pharmaceutical Preparations
- Sector
- PLL Basic Materials
- RVPHW Health Care
- Exchange
- PLL Nasdaq
- RVPHW Nasdaq
- Market Cap
- PLL N/A
- RVPHW N/A
- IPO Year
- PLL 2017
- RVPHW N/A
- Fundamental
- Price
- PLL $6.57
- RVPHW $0.05
- Analyst Decision
- PLL Hold
- RVPHW
- Analyst Count
- PLL 7
- RVPHW 0
- Target Price
- PLL $18.79
- RVPHW N/A
- AVG Volume (30 Days)
- PLL 244.2K
- RVPHW 22.4K
- Earning Date
- PLL 05-08-2025
- RVPHW 03-14-2025
- Dividend Yield
- PLL N/A
- RVPHW N/A
- EPS Growth
- PLL N/A
- RVPHW N/A
- EPS
- PLL N/A
- RVPHW N/A
- Revenue
- PLL $99,877,000.00
- RVPHW N/A
- Revenue This Year
- PLL $10.04
- RVPHW N/A
- Revenue Next Year
- PLL $36.50
- RVPHW N/A
- P/E Ratio
- PLL N/A
- RVPHW N/A
- Revenue Growth
- PLL 150.84
- RVPHW N/A
- 52 Week Low
- PLL $5.15
- RVPHW $0.13
- 52 Week High
- PLL $16.59
- RVPHW $0.15
- Technical
- Relative Strength Index (RSI)
- PLL 49.89
- RVPHW N/A
- Support Level
- PLL $6.27
- RVPHW N/A
- Resistance Level
- PLL $7.08
- RVPHW N/A
- Average True Range (ATR)
- PLL 0.49
- RVPHW 0.00
- MACD
- PLL 0.13
- RVPHW 0.00
- Stochastic Oscillator
- PLL 73.58
- RVPHW 0.00
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.